Allergan Cash Flow - Quarterly (NYSE:AGN)

Add to My Stocks
$173.18 $0.77 (0.44%) AGN stock closing price Jun 15, 2018 (Closing)

The Allergan cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. This statement shows details about the cash generated and spent during a particular quarter, while the other two statements give details about Allergan profits and Allergan debt. Items like capital purchases, bank loan payments etc. which have a direct impact on the cash position of a company come out through the statemement of cash flows and help an investor who undertakes the Allergan stock analysis. Allergan generated $1.46B cash from operating activities in till this quarter of 2018 Q1. Allergan saw a inflow of $2.93B from investing activities till 2018 Q1.

View and download details of Allergan cash flows for latest & last 40 quarters
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q4
Net Income Cash Flow
-283.9M-4.12B-7.24B-3.29B-2.56B14.98B14.98B-243.5M256.4M3.92B
Depreciation Depletion Amortization Cash-Flow1.76B7.53B5.54B3.68B1.81B6.72B5.04B3.37B1.72B7.49B
Net Increase (Decrease) in Assets Liabilities297.3M933.9M93.39M219.1M-235.8M-726.5M-300.3M-760.1M-357.7M-1.27B
Cash From (used in) Discontinued Operations----------
Other Adjustments Net-315.1M1.53B5.43B1.75B1.71B-19.55B-18.21B236.7M-400.4M-5.6B
Net Cash from (used by) Operating Activities
1.46B5.87B3.83B2.35B723.3M1.43B1.51B2.6B1.22B4.53B
Increase (Decrease) in Prop Plant And Equipment-35.3M-342.8M-228.2M-132.9M-32.5M-298.1M-217.2M-168.3M-72.8M-314.8M
Acquisition Disposition of Subsidiaires--5.29B-5.29B-5.29B-2.87B32.61B33.23B---37.51B
Increase (Decrease) in Investments3.43B5.37B-8.43B6.41B3.27B-7.97B40M-19M858.7M
Other Cash Inflow (Outflow) from Investment Activities-466M-614.3M13.87B-586.3M-346.3M-2M-15.45B25.5M--154.7M
Net Cash from (used by) Investment Activities
2.93B-878M-82.3M400M14.2M24.33B17.61B-142.8M-53.8M-37.12B
Issuance (Purchase) of Equity Shares-1.4B-309.6M130.8M89.5M23.1M-14.9B-2.62B40M16.4M9.11B
Issuance (Repayment) of Debt Securities-3.61B-2.86B-2.55B-3.06B-1.02B-9.8B1.05B-2.94B45.79M25B
Increase (Decrease) in Bank & Other Borrowings-------10.83B---
Payment of Dividends & Other Cash Distributions-319.5M-1.22B-917M-611.9M-305.8M-278.4M-208.8M-139.2M-69.6M-208.1M
Other Cash from (used by) Financing Activities129M-532.2M-532.7M-17.5M-76.3M-140.7M-51.1M-31.9M2.29M-464.8M
Net Cash from (used by) Financing Activities
-5.21B-4.92B-3.87B-3.6B-1.37B-25.12B-12.66B-3.07B-5.1M33.44B
Effect of Exchange Rate Changes on Cash-5.3M21.4M19.1M11.5M6.3M-8.5M4.3M2M5.2M-6.5M
Net Change in Cash & Cash Equivalents
-822.4M93.2M-111.3M-837.1M-631.1M628M6.46B-606.5M1.16B846M
Cash & Equivalents at Beginning of Year1.72B1.1B250M329M319M209.3M282.8M201.4M507.6M204.55M
Cash & Equivalents at Year End994.8M1.82B1.61B886.9M1.09B1.72B7.55B489.5M2.26B1.1B
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Allergan stock price history provides insight into historical stock price fluctuations, and Allergan stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:

  • Allergan has cash of $994.8M on hand. A healthy amount of cash on hand is necessary for any company. Cash has an opportunity cost associated with it, and too much cash in bank may mean that the firm has no or limited growth plans. Hence its important to track the Net Change in Cash and Cash Equivalents along with the Allergan stock price.
  • Allergan increased its cash from operating activities to $1.46B till 2018 Q1. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash Flow from investment activities: Allergan generated $2.93B cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash flow from financing activities shows the flow of cash between Allergan and its owners and creditors and was $-5.21B till 2018 Q1. Financing activities allow a company to raise capital, and repay bondholders.

Key Financial Ratios For Allergan Cash Flow

FCF margin
0.39

Quarterly Cash Flow Statements For Allergan plc Ordinary Shares Peers

Astrazeneca cash flow, GlaxoSmithKline cash flow, Merck cash flow, Mylan cash flow, Teva Pharmaceutical cash flow